Median progression-free survival was 6 months.
中位无进展生存期为6个月。
Coprimary end points were rates of overall and progression-free survival.
共同的初级终点指标为总生存率和无进展生存率。
In both studies, the primary efficacy endpoint was progression-free survival.
在两项研究中，主要功效评估指标是无进展生存期。
The primary end point was amended from overall survival (OS) to progression-free survival (PFS).
首要观察终点从总生存期(OS)改为无进展生存期(PFS)。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
两治疗组的无进展生存期和总生存期都没有明显的差异。
Overall survival and progression-free survival also did not differ in the two groups, the researchers note.
研究人员提到，在两组中总生存期和无进展生存也没有差异。
The primary end point was progression-free survival; secondary end points included the objective response rate, overall survival, and safety.
主要研究终点为无进展生存（PFS），次级研究终点包括客观有效率、总生存和安全性。
Cox proportional-hazards analysis of progression-free survival according to baseline characteristics favored sunitinib in all subgroups studied.
在研究的所有亚组中，根据基线特征进行的PFS的Cox风险比例分析均有利于舒尼替尼。
The median progression-free survival period with the drug combination was 11.8 months, twice as long as the 5.9 months achieved with paclitaxel alone.
药物联用的中值无进展存活期为11.8个月，是用单独紫杉醇获得的5.9个月的两倍。
Thus, surrogate endpoints like response rate and progression-free survival are commonly accepted, although all parties involved realize the risk involved.
因此，替代终点如反应率和无进展生存率被普遍接受，尽管各方意识到风险所在。
Although the study was not designed to compare the Avastin doses, a similar treatment effect in progression-free survival was observed between the two arms.
虽然这项研究并不是用来比较阿瓦斯丁剂量，一项类似的治疗效果，在级数无生存观察到两国之间的武器。
The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms versus the control regimen.
这项研究的主要目的是，要表现出优势，循序渐进无生存的阿瓦斯丁都含有治疗武器银两控制水情。
However, neither overall survival after the start of antitumor therapy nor progression-free survival after gefitinib therapy was significantly different between groups.
然而，无论是抗肿瘤治疗开始后的整体生存率，还是吉非替尼治疗后无恶化生存率在上述两组病人中并无明显差异。
FDA gave its blessing based on a trial showing it offered breast cancer patients an extra 5.5 months of "progression-free survival," time when their tumors weren't growing.
FDA是基于阿瓦斯丁可以让患者的肿瘤在5个半月内都不增长的研究，批准了阿瓦斯丁的使用许可。
This study aims to analyze the factors that influence the progression-free survival time of PCa patients after endocrine therapy in an attempt to improve the prognosis of the disease.
目的：前列腺癌内分泌治疗后发现进展速度存在较大差异，为了改善其预后，本文探讨前列腺癌内分泌治疗后无进展生存期的影响因素。
Most scientific experts consider this benefit "progression-free survival," sufficient for full approval, and many oncologists have been using Avastin as an "off-label" drug for this purpose.
多数的专家认为这得益于“无进展生存”，阿瓦斯丁已经被许多肿瘤学家作为“未贴签”药物用于治疗，足以完全通过审批。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
To determine which radiotherapy regimens for oral cavity and oropharyngeal cancers result in increased overall survival, disease free survival, progression free survival and locoregional control.
确定何种口腔及口咽癌的放射治疗方式能够增加整体存活、无病存活、无疾病进展存活以及局部区域控制。
All 185 patients were included in the analysis of progression-free and overall survival.
全部185名患者参与了无疾病进展及总体生存的分析。
All 185 patients were included in the analysis of progression-free and overall survival.
全部185名患者参与了无疾病进展及总体生存的分析。
应用推荐